KPRX Q2 2026 Earnings Summary

$KPRX Q2 2026 Earnings Results & Recap

Reported GAAP EPS of -$0.34 up 37.04% YoY

Bullish Highlights

Read Next

JPMorgan Calls CIFR Stock ‘Substantially Undervalued’ Amid Fresh Price Target Cuts

Anushka Basu

• Kiora Pharmaceuticals ended the second quarter of 2026 with approximately $16.8 million in cash and short-term investments, which provides an expected operating runway into late 2028 for the company.
• Kiora Pharmaceuticals secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront, to support the company's development pipeline and ongoing clinical trial activities.
• Kiora Pharmaceuticals advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort, with development costs fully reimbursed under the company's collaboration with Tha Open Innovation.

Key Risks

• Kiora Pharmaceuticals reported a net loss of approximately $2.1 million for the second quarter of 2026, which is a decrease compared to the net loss of $2.2 million in 2025.
• Kiora Pharmaceuticals remains a clinical-stage biotechnology company that faces significant risks and uncertainties regarding its ability to conduct and complete clinical trials on a timely basis for its product candidates.
• Kiora Pharmaceuticals relies on the completion of potential strategic transactions to satisfy warrant acceleration milestone provisions from a recent private placement to provide additional capital for the company's operations.